API
< Back to all clusters
[HEALTH] · United States · 5 sources

started · updated

Cabotegravir PrEP stays effective for women despite injection delays

A US longitudinal study of routine clinical care (the OPERA cohort) followed 315 women using the long‑acting injectable cabotegravir (marketed as Apretude) for HIV pre‑exposure prophylaxis. Over a median of 13 months, none of the participants contracted HIV, even when some experienced short delays before receiving maintenance injections. The findings suggest the formulation retains protective efficacy despite occasional missed doses, addressing common adherence challenges associated with daily oral PrEP.

The results support broader implementation of long‑acting injectable PrEP as a viable option for women, potentially improving uptake and persistence in HIV prevention programs.

Entities

Apretude · Cabotegravir · OPERA longitudinal cohort · United States